Show simple item record

dc.contributor.authorBaka, Sofia
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorFerraldeschi, Roberta
dc.contributor.authorAshcroft, Linda
dc.contributor.authorThatcher, Nick
dc.contributor.authorTaylor, Pat
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorLorigan, Paul C
dc.date.accessioned2009-04-02T16:04:58Z
dc.date.available2009-04-02T16:04:58Z
dc.date.issued2008-08-05
dc.identifier.citationPhase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. 2008, 99 (3):442-7 Br. J. Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid18665190
dc.identifier.doi10.1038/sj.bjc.6604480
dc.identifier.urihttp://hdl.handle.net/10541/59193
dc.description.abstractThis randomised trial compared platinum-based to anthracycline-based chemotherapy in patients with small-cell lung cancer (limited or extensive stage) and
dc.language.isoenen
dc.subjectSmall-Cell Lung Canceren
dc.subjectLung Canceren
dc.subjectChemotherapyen
dc.subjectRandomized Clinical Trialen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarcinoma, Small Cell
dc.subject.meshCisplatin
dc.subject.meshCyclophosphamide
dc.subject.meshDoxorubicin
dc.subject.meshEtoposide
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMonitoring, Physiologic
dc.subject.meshSurvival Analysis
dc.titlePhase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractThis randomised trial compared platinum-based to anthracycline-based chemotherapy in patients with small-cell lung cancer (limited or extensive stage) and <or=2 adverse prognostic factors. Patients were randomised to receive six cycles of either ACE (doxorubicin 50 mg/m(2) i.v., cyclophosphamide 1 g/m(2) i.v. and etoposide 120 mg/m(2) i.v. on day 1, then etoposide 240 mg/m(2) orally for 2 days) or PE (cisplatin 80 mg/m(2) and etoposide 120 mg/m(2) i.v. on day 1, then etoposide 240 mg/m(2) orally for 2 days) given for every 3 weeks. For patients where cisplatin was not suitable, carboplatin (AUC6) was substituted. A total of 280 patients were included (139 ACE, 141 PE). The response rates were 72% for ACE and 77% for PE. One-year survival rates were 34 and 38% (P=0.497), respectively and 2-year survival was the same (12%) for both arms. For LD patients, the median survival was 10.9 months for ACE and 12.6 months for PE (P=0.51); for ED patients median survival was 8.3 months and 7.5 months, respectively. More grades 3 and 4 neutropenia (90 vs 57%, P<0.005) and grades 3 and 4 infections (73 vs 29%, P<0.005) occurred with ACE, resulting in more days of hospitalisation and greater i.v. antibiotic use. ACE was associated with a higher risk of neutropenic sepsis than PE and with a trend towards worse outcome in patients with LD, and should not be studied further in this group of patients.


This item appears in the following Collection(s)

Show simple item record